Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Original article

Vol. 144 No. 3536 (2014)

The outcome of community-acquired pneumonia in patients with chronic lung disease

  • Frank Dusemund
  • Joannis Chronis
  • Florent Baty
  • Werner Christian Albrich
  • Martin Hugo Brutsche
DOI
https://doi.org/10.4414/smw.2014.14013
Cite this as:
Swiss Med Wkly. 2014;144:w14013
Published
24.08.2014

Summary

BACKGROUND: The impact of chronic lung diseases on outcome in community-acquired pneumonia (CAP) is not well established. We aimed to investigate the outcome of adult CAP-patients with underlying chronic obstructive pulmonary disease (COPD), asthma or interstitial lung disease (ILD) in a case-control study.

METHODS: We used a nationwide database including all hospitalisations in Switzerland from 2002 to 2010. Endpoints were the incidence of lung abscess, parapneumonic pleural effusion, empyema, acute respiratory distress syndrome, in-hospital mortality and length of stay.

RESULTS: We found less disease-related complications of CAP in COPD (n = 17,075) and asthma (n = 2700) patients compared with their controls. This difference was mainly related to a lower incidence of pleural effusion (COPD: 4.3% vs 4.9%, p = 0.011; asthma: 3.4% vs 5.2%, p <0.001). In-hospital mortality was lower in the COPD and – much more pronounced – asthma cohorts (COPD: 5.8% vs 6.7%, p <0.001; asthma: 1.4% vs 4.8%, p <0.001). For ILD (n = 916), the complication rate was similar as compared to the control group, whereas in-hospital mortality was markedly higher (16.3% vs 6.8%, p <0.001).

CONCLUSIONS: These rather unexpected results should be viewed as hypothesis generating, with various possible explanations for our findings. These include the possible influence of inhaled corticosteroid therapy, a possibly higher awareness of general practitioners and hospital physicians while treating patients with chronic lung diseases, a different infective agent spectrum or a different immune response.

References

  1. http://www.cdc.gov/nchs/data/nhds/2average/2010ave2_firstlist.pdf
  2. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America, American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(Suppl2):S27.
  3. Almirall J, Bolíbar I, Balanzó X, González CA. Risk factors for community-acquired pneumonia in adults: a population-based case-control study. EurRespir J. 1999;13(2):349.
  4. Chalmers JD, Singanayagam A, Murray MP, Scally C, Fawzi A, Hill AT. Risk factors for complicated parapneumonic effusion and empyema on presentation to hospital with community-acquired pneumonia. Thorax. 2009;64(7):592–7.
  5. Cillóniz C, Ewig S, Polverino E, Muñoz-Almagro C, Marco F, Gabarrús A, et al. Pulmonary complications of pneumococcal community-acquired pneumonia: incidence, predictors, and outcomes. Clin Microbiol Infect. 2012;18(11):1134–42.
  6. Ishiguro T, Takayanagi N, Yamaguchi S, Yamakawa H, Nakamoto K, Takaku Y, et al. Etiology and factors contributing to the severity and mortality of community-acquired pneumonia. Intern Med. 2013;52(3):317–24.
  7. Eurich DT, Lee C, Marrie TJ, Majumdar SR. Inhaled corticosteroids and risk of recurrent pneumonia: a population-based, nested case-control study. Clin Infect Dis. 2013;57(8):1138–44.
  8. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775–89.
  9. Calverley PM, Stockley RA, Seemungal TA, Hagan G, Willits LR, Riley JH, et al. Reported pneumonia in patients with COPD: findings from the INSPIRE study. Chest. 2011;139(3):505–12.
  10. Singh S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med. 2009;169(3):219–29.
  11. Drummond MB, Dasenbrook EC, Pitz MW, Murphy DJ, Fan E. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2008;300(20):2407–16.
  12. Sellares J, López-Giraldo A, Lucena C, Cilloniz C, Amaro R, Polverino E, et al. Influence of Previous Use of Inhaled Corticoids on the Development of Pleural Effusion in Community-Acquired Pneumonia. Am J Respir Crit Care Med. 2013;187(11):1241–8.
  13. Loke YK, Kwok CS, Wong JM, Sankaran P, Myint PK. Chronic obstructive pulmonary disease and mortality from pneumonia: meta-analysis. Int J Clin Pract. 2013;67(5):477–87.
  14. Marzoratti L, Iannella HA, Waterer GW. Inhaled corticosteroids and the increased risk of pneumonia. Ther Adv Respir Dis. 2013;7(4):225–34.
  15. Yawn BP, Li Y, Tian H, Zhang J, Arcona S, Kahler KH. Inhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: a retrospective claims data analysis. Int J COPD. 2013;8:295–304.
  16. To M, To Y, Yamada H, Ogawa C, Otomo M, Suzuki N, et al. Influence of inhaled corticosteroids on community-acquired pneumonia in patients with bronchial asthma. Intern Med. 2004;43(8):674–8.
  17. Sze MA, Hogg JC, Sin DD. Bacterial microbiome of lungs in COPD. Int J Chron Obstruct Pulmon Dis. 2014;21(9):229–38.
  18. Segal LN, Rom WN, Weiden MD. Lung Microbiome for Clinicians. New Discoveries about Bugs in Healthy and Diseased Lungs. Ann Am Thorac Soc. 2014;11(1):108–16.
  19. Martinez FJ, Erb-Downward JR, Huffnagle GB. Significance of the microbiome in chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2013;Suppl:170–9.
  20. Crisafulli E, Menéndez R, Huerta A, Martinez R, Montull B, Clini E, et al. Systemic inflammatory pattern of patients with community-acquired pneumonia with and without COPD. Chest. 2013;143(4):1009–17.
  21. Wertheim HF, Vos MC, Ott A, van Belkum A, Voss A, Kluytmans JA, et al. Risk and outcome of nosocomial Staphylococcus aureus bacteraemia in nasal carriers versus non-carriers. Lancet. 2004;364(9435):703–5.
  22. Derrien M, Van Baarlen P, Hooiveld G, Norin E, Müller M, de Vos WM. Modulation of Mucosal Immune Response, Tolerance, and Proliferation in Mice Colonized by the Mucin-Degrader Akkermansia muciniphila. Front Microbiol 2011;2:166.

Most read articles by the same author(s)